Head-to-Head

AIM ImmunoTech Inc. vs. Kymera Therapeutics, Inc. Common Stock

AIM

AIM ImmunoTech Inc.

$0.25 +12.05%

VS KYMR

Kymera Therapeutics, Inc. Common Stock

$117.39 +2.60%

Kymera Therapeutics, Inc. Common Stock (KYMR) comes out ahead, leading on 2 of 3 compared factors.

Size & Scale

AIMKYMR
Market Cap $6.69 million $9.76 billion
Revenue (TTM) — $105.00 million
Net Income (TTM) — $-299,601,000

KYMR leads on 1 of 1 size & scale factors.

Valuation

AIMKYMR
Price / Book 0.57 6.47
Price / Sales — 92.96

AIM leads on 1 of 1 valuation factors.

Profitability

AIMKYMR
Net Margin — -285.34%
Return on Equity — -19.85%

AIM and KYMR split the profitability factors evenly.

Risk & Sentiment

AIMKYMR
Short Interest 0.32% 0.24%

KYMR leads on 1 of 1 risk & sentiment factors.

Dig deeper: AIM overview, AIM financials, KYMR overview, KYMR financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.